Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DM13FX4)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
(Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-Hydroxyoct-1-enyl]-3-oxabicyclo[221]heptan-6-yl]hept-5-enoic acid; U 46619; MLS000028857; CHEMBL521784; U-46619; 56985-40-1; SMR000058897; (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[221]hept-5-yl]-5-heptenoic acid; 9a,11a-Methanoepoxy-15-hydroxyprosta-5,13-dienoic acid; 9,11-Methanoepoxy PGH2; 11alpha,9alpha-epoxymethano-PGH2; 9alpha-PGM; (Z)-7-[(1S,4R,5R,6S)-5-[(E,3S)-3-hydroxyoct-1-enyl]-3-oxabicyclo[221]heptan-6-yl]hept-5-enoic acid; 9alpha,11alpha-Methanoepoxy-PGF2alpha; Opera_ID_380; [3H]U46619; 9,11-Dideoxy-9alpha,11alpha-methanoepoxy PGF2alpha; U 46619
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Breast
Breast adenocarcinoma
Colon
Colorectal adenocarcinoma
Hematopoietic system
Normal
Kidney
Normal (Immortalized)
Liver
Hepatoblastoma
Lung
Lung adenocarcinoma
Non-small cell lung carcinoma
Prostate
Prostate carcinoma
Skin
Melanoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
